Indication

Bronchiectasis

Bronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls. Read more about Bronchiectasis

6 drugs 6 manufacturers

Advertisement

Drugs that treat it

Common Bronchiectasis therapies.

Showing 1–6 of 6 drugs

ACETYLCYSTEINE

MUCOLYTICS·RESPIRATORY CYSTIC FIBROSIS·+6
American Regent

ACETYLCYSTEINE

MUCOLYTICS·RESPIRATORY CYSTIC FIBROSIS·+6
CAMERON PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Bronchiectasis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Bronchiectasis.

Bronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls.

Pathophysiologically, it arises from a self-perpetuating cycle of impaired mucociliary clearance, chronic neutrophilic airway inflammation, persistent bacterial infection, and progressive tissue remodeling.

It can affect pediatric or adult populations and frequently develops secondary to conditions such as severe respiratory infections, cystic fibrosis, primary ciliary dyskinesia, or underlying immune deficiencies.

Defining clinical features include a chronic cough productive of copious, often purulent sputum, recurrent infectious exacerbations, dyspnea, and progressive airflow obstruction.

Personalize your experience

Follow Bronchiectasis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it